Vancomycin, linezolid and daptomycin susceptibility pattern among clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) from Sub- Himalyan Center

ABSTRACT

INTRODUCTION: The efficacy of vancomycin, drug of choice for methicillin-resistant Staphylococcus aureus (MRSA), has become questionable due to the emergence of MRSA isolates with reduced susceptibility. The present study was conducted to determine the vancomycin, linezolid, and daptomycin susceptibility pattern in clinical isolates of MRSA and to observe minimum inhibitory concentration (MIC) creep over 2 years if any.

MATERIALS AND METHODS: MIC of vancomycin, linezolid, and daptomycin were determined by E-test in 198 MRSA isolates and their MIC 50, MIC 90, and geometric mean MIC were calculated.

RESULTS: While all isolates were sensitive to vancomycin, linezolid, and daptomycin, MIC 90 of vancomycin increased from 1.5 µg/ml in 2015 to 2 µg/ml in 2016. The percentage of isolates with vancomycin MIC >2 µg/ml doubled in 2016 (12.9%) as compared to 2015 (6.1%). MIC 90 for linezolid remained steady as 3 µg/ml, but geometric mean MIC increased from 2.20 µg/ml in 2015 to 2.29 µg/ml in 2016, and more than 40% isolates showed MIC 3 µg/ml. MIC 90 and geometric mean MIC of daptomycin decreased from 0.75 µg/ml to 0.5 µg/ml and 0.50 µg/ml to 0.36 µg/ml in 2015 and 2016, respectively.

CONCLUSION: MIC creep was observed with vancomycin. Although linezolid MIC was within the susceptible zone, more than 40% strains showing MIC 3 µg/ml may herald the future development of either resistant or heteroresistant. Daptomycin showed good sensitivity against MRSA isolates. Therefore, it could be considered as an alternative agent for the treatment of infections caused by MRSA. However, it should be reserved where this class has a clear therapeutic advantage over other anti-MRSA drugs.

Key words

Daptomycin - linezolid - methicillin-resistant Staphylococcus aureus - vancomycin creep

Publication History

Received: 21 May 2017

Accepted: 03 August 2017

Article published online:
19 February 2020

• REFERENCES

• 1 Niveditha N, Sujatha S. Worrisome trends in rising minimum inhibitory concentration values of antibiotics against methicillin resistant Staphylococcus aureus - Insights from a tertiary care center, South India. Braz J Infect Dis 2015;19:585-9.
• 2 Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC creep'): Implications for therapy. F1000 Med Rep 2012;4:4.
• 3 Chang W, Xiaoling M, Gao P, Lv X, Lu H, Chen F. Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China. Indian J Med Microbiol 2015;33:262-6.
• 4 Basireddy S, Singh M, Ali S, Kabra V. CFR gene mediated linezolid resistance in staphylococcal isolates. Int J Pharm Bio Sci 2014;5:139-9.
• 5 Dortet L, Anguel N, Fortineau N, Richard C, Nordmann P.In vivo acquired daptomycin resistance during treatment of methicillin-resistant Staphylococcus aureus endocarditis. Int J Infect Dis 2013;17:e1076-7.
• 6 Winn WC, Allen SD, Allen S, Janda WM, Koneman EW, Schrekenberger PC, et al.. Gram positive Cocci, Part 1: In Staphylococci and related Gram positive cocci. Koneman Color Atlas and Textbook of Diagnostic Microbiology. 6th ed. Philadelphia; Lippincott William and Wilkins: 2006. p. 624-73.
• 7 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 26^th Informational Supplement. (M100-S26). Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2014.
• 8 Durmaz B, Durmaz R, Sahin K. Methicillin-resistance among Turkish isolates of Staphylococcus aureus strains from nosocomial and community infections and their resistance patterns using various antimicrobial agents. J Hosp Infect 1997;37:325-9.
• 9 Debnath A, Chikkaswamy BK. Antibiogram and susceptibility pattern of methicillin resistant Staphylococcus aureus collected from various clinical samples in Bengaluru. Asian J Pharm Clin Res 2015;8:260-4.
• 10 Lu C, Guo Y, Wang S, Wang Z, Chen L, Lv J, et al.. Decreased vancomycin MICs among methicillin-resistant Staphylococcus aureus clinical isolates at a Chinese tertiary hospital over a 12-year period. Front Microbiol 2016;7:1714.
• 11 Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Antimicrobial susceptibility of gram-positive bacterial isolates from the Asia-Pacific Region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: A SENTRY program report (2003-2004). Int J Antimicrob Agents 2007;30:143-9.
• 12 Joshi S, Ray P, Manchanda V, Bajaj J, Chitnis DS, Gautam V, et al.. Methicillin resistant Staphylococcus aureus (MRSA) in India: Prevalence and susceptibility pattern. Indian J Med Res 2013;137:363-9.
• 13 Diederen B, Duijn I, Willemse P, Jan A, Kluytmans J. In vitro activity of daptomycin against methicillin resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains. Antimicrob Agents Chemother 2006;50:3189-91.
• 14 Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-2005. J Antimicrob Chemother 2007;60:788-94.
• 15 Rai S, Niranjan DK, Kaur T, Singh NP, Hada V, Kaur IR, et al. Detection of the classical G2576U mutation in linezolid resistant Staphylococcus aureus along with isolation of linezolid resistant Enterococcus faeciumfrom a patient on short-term linezolid therapy:First report from India. Indian J Med Microbiol 2015;33:21-4.
• 16 Chitnis S, Katara G, Hemvani N, Pareek S, Chitnis DS.In vitro activity of daptomycin and linezolid against methicillin resistant staphylococcus aureus & vancomycin resistant enterococci isolated from hospitalized cases in central India. Indian J Med Res 2013;137:191-6.